The purpose of this study is to determine whether tropicamide + phenylephrine cyclopentolate
+ applied for once waiting 30 minutes to retinoscopy (new scheme) is not inferior to apply
cyclopentolate alone and wait 45 minutes to retinoscopy (traditional scheme)
Atropine for Children and Adolescent Myopia Progression Study
Unknown status
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
2019-05-08
Investigators are going to conduct a randomized controlled trial that myopic children are
randomly allocated into two groups: combined use of 1% atropine and 0.01% atropine
(experimental group) and 0.01% atropine (control group) in order to explore a better way to
control myopia progression and eliminate adverse effects at the same time, provide reliably
evidence for clinical guideline of atropine use in children, and investigate the mechanism of
atropine on eyes.
Atropine for Children and Adolescent Myopia Progression Study
Unknown status
Shanghai Eye Disease Prevention and Treatment Center
Phase 4
2019-05-08
Investigators are going to conduct a randomized controlled trial that myopic children are
randomly allocated into two groups: combined use of 1% atropine and 0.01% atropine
(experimental group) and 0.01% atropine (control group) in order to explore a better way to
control myopia progression and eliminate adverse effects at the same time, provide reliably
evidence for clinical guideline of atropine use in children, and investigate the mechanism of
atropine on eyes.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
